Selecting antipsychotics in schizophrenia: lessons from CATIE.
Haddad
Peter
P
Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.
Dursun
Serdar Murat
SM
D000208:Acute Disease; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D006801:Humans; D000077152:Olanzapine; D010352:Patient Dropouts; D010546:Perphenazine / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010546:Perphenazine; D000077152:Olanzapine